Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value
$0.18+0.00 (+0.95%)
Close on Nov 13, 2026Market cap $8.01MP/E –Yield –
Vistagen Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Vistagen Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -2541.9%. For fiscal 2026 it was -5683.7%, against -11517.1% the year before. The highest annual figure on record is -317.0% in fiscal 2011.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -5683.7% | +5833.4 |
| FY2025 | Mar 31, 2025 | -11517.1% | −8413.6 |
| FY2024 | Mar 31, 2024 | -3103.5% | +1204.8 |
| FY2022 | Mar 31, 2022 | -4308.3% | −2662.2 |
| FY2021 | Mar 31, 2021 | -1646.1% | −826.2 |
| FY2017 | Mar 31, 2017 | -819.9% | +2569.9 |
| FY2013 | Mar 31, 2013 | -3389.8% | −2716.0 |
| FY2012 | Mar 31, 2012 | -673.8% | −356.8 |
| FY2011 | Mar 31, 2011 | -317.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | -7925.4% | −152.9 |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -904.3% | +5572.7 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -3595.1% | +2866.5 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -6450.8% | +1323.5 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -7772.5% | +6669.2 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -6477.0% | −711.1 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -6461.5% | −4543.3 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -7774.3% | −5335.5 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -14441.7% | −10488.0 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -5766.0% | +1188.0 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -1918.2% | +3507.6 |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -2438.8% | +3937.5 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -3953.7% | +38848.9 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -6954.0% | −4010.1 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -5425.8% | −1850.4 |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -6376.4% | −4187.9 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -42802.6% | −41395.6 |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -2943.9% | −1254.0 |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -3575.4% | −2589.3 |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -2188.4% | −1977.5 |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -1407.0% | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -1689.8% | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -986.1% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -211.0% | – |
See a number that looks wrong?